Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company was incorporated in 2018 is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.
Over the last 12 months, insiders at Immunovant, Inc. have bought $336.9M and sold $9.55M worth of Immunovant, Inc. stock.
On average, over the past 5 years, insiders at Immunovant, Inc. have bought $91.7M and sold $6.2M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Roivant Sciences Ltd. () — $336.9M.
The last purchase of 16,845,010 shares for transaction amount of $336.9M was made by Roivant Sciences Ltd. () on 2025‑01‑13.
2025-01-22 | Sale | Chief Technology Officer | 2,195 0.0015% | $23.59 | $51,780 | -6.31% | ||
2025-01-22 | Sale | Chief Medical Officer | 2,657 0.0018% | $23.59 | $62,679 | -6.31% | ||
2025-01-15 | Sale | Chief Executive Officer | 8,767 0.0059% | $23.83 | $208,900 | -9.63% | ||
2025-01-15 | Sale | Chief Medical Officer | 2,383 0.0016% | $23.83 | $56,782 | -9.63% | ||
2025-01-15 | Sale | Chief Financial Officer | 2,298 0.0016% | $23.83 | $54,757 | -9.63% | ||
2025-01-13 | 16.85M 10.1065% | $20.00 | $336.9M | -2.26% | ||||
2025-01-08 | Sale | Chief Executive Officer | 5,105 0.0035% | $24.10 | $123,031 | -4.46% | ||
2025-01-08 | Sale | Chief Financial Officer | 4,105 0.0028% | $24.10 | $98,931 | -4.46% | ||
2024-12-02 | Sale | director | 5,425 0.0037% | $28.54 | $154,830 | -14.94% | ||
2024-12-02 | Sale | director | 7,750 0.0052% | $28.54 | $221,185 | -14.94% | ||
2024-11-20 | Sale | Chief Executive Officer | 16,692 0.0111% | $25.45 | $424,811 | -5.27% | ||
2024-11-20 | Sale | Chief Medical Officer | 3,353 0.0022% | $25.45 | $85,334 | -5.27% | ||
2024-11-20 | Sale | Chief Financial Officer | 4,174 0.0028% | $25.45 | $106,228 | -5.27% | ||
2024-11-20 | Sale | Chief Legal Officer | 3,650 0.0024% | $25.45 | $92,893 | -5.27% | ||
2024-10-23 | Sale | Chief Legal Officer | 4,361 0.003% | $29.53 | $128,780 | -12.69% | ||
2024-10-23 | Sale | Chief Technology Officer | 2,740 0.0019% | $29.53 | $80,912 | -12.69% | ||
2024-10-23 | Sale | Chief Medical Officer | 3,189 0.0022% | $29.53 | $94,171 | -12.69% | ||
2024-10-16 | Sale | Chief Executive Officer | 9,095 0.0063% | $28.79 | $261,845 | -9.02% | ||
2024-10-16 | Sale | Chief Medical Officer | 3,188 0.0022% | $28.79 | $91,783 | -9.02% | ||
2024-10-16 | Sale | Chief Financial Officer | 3,271 0.0023% | $28.79 | $94,172 | -9.02% |
Roivant Sciences Ltd. | 96650341 56.9094% | $20.41 | 6 | 0 | +39.82% | |
Salzmann Peter | Chief Executive Officer | 964225 0.5678% | $20.41 | 0 | 29 | |
Butchko Julia G. | Chief Development Officer | 440959 0.2596% | $20.41 | 1 | 22 | <0.0001% |
Macias William L. | Chief Medical Officer | 359408 0.2116% | $20.41 | 0 | 20 | |
Barnett Eva Renee | Chief Financial Officer | 324766 0.1912% | $20.41 | 0 | 21 | |
Levine Mark S. | Chief Legal Officer | 319228 0.188% | $20.41 | 0 | 17 | |
Stout Jay S | Chief Technology Officer | 139991 0.0824% | $20.41 | 0 | 4 | |
Geffner Michael | Chief Medical Officer | 132314 0.0779% | $20.41 | 0 | 5 | |
Hughes Douglas J. | director | 119585 0.0704% | $20.41 | 1 | 1 | <0.0001% |
Pande Atul | director | 86663 0.051% | $20.41 | 2 | 2 | +99.07% |
WONG RODERICK | Chief Executive Officer | 902498 0.5314% | $20.41 | 22 | 0 | +118.39% |
MIGAUSKY GEORGE V | director | 109808 0.0647% | $20.41 | 1 | 1 | <0.0001% |
Fromkin Andrew J. | director | 88658 0.0522% | $20.41 | 1 | 1 | <0.0001% |
Increased Positions | 95 | +43.38% | 12M | +16.67% |
Decreased Positions | 97 | -44.29% | 8M | -10.41% |
New Positions | 20 | New | 2M | New |
Sold Out Positions | 37 | Sold Out | 3M | Sold Out |
Total Postitions | 217 | -0.91% | 79M | +6.26% |
Fmr Llc | $272,567.00 | 7.38% | 12.54M | +2M | +19.59% | 2024-09-30 |
Vanguard Group Inc | $144,762.00 | 3.92% | 6.66M | +149,047 | +2.29% | 2024-09-30 |
Blackrock, Inc. | $109,855.00 | 2.97% | 5.05M | +137,023 | +2.79% | 2024-09-30 |
Deep Track Capital, Lp | $94,514.00 | 2.56% | 4.35M | +1M | +50.76% | 2024-09-30 |
Armistice Capital, Llc | $77,134.00 | 2.09% | 3.55M | +151,091 | +4.45% | 2024-09-30 |
T. Rowe Price Investment Management, Inc. | $72,416.00 | 1.96% | 3.33M | +2M | +104.96% | 2024-09-30 |
State Street Corp | $65,706.00 | 1.78% | 3.02M | +303,386 | +11.16% | 2024-09-30 |
Perceptive Advisors Llc | $51,714.00 | 1.4% | 2.38M | +454,976 | +23.65% | 2024-09-30 |
Viking Global Investors Lp | $50,456.00 | 1.37% | 2.32M | 0 | 0% | 2024-09-30 |
Alpine Global Management, Llc | $40,930.00 | 1.11% | 1.88M | -25,000 | -1.31% | 2024-09-30 |